

### Activity Overview

The meeting is designed to enhance knowledge and increase competency in the treatment of cardiovascular disease.

### Target Audience

This activity is designed for an audience of physicians, physician associates, pharmacists, and nurses.

### Learning Objectives

Upon completion of the educational activity, participants should be able to:

- Discuss the indications for and the treatment of tricuspid valve disease.
- Implement tools, resources, and regulations that impact the cardiovascular business practice environment necessary to remain financially successful in an era of payment reform.
- Characterize the physiologic effects of obesity and its comorbidities on the cardiovascular system.
- Compare and contrast the most current treatment strategies for atrial fibrillation and anticoagulation.
- Review the utilization of AI for cardiovascular imaging.
- Examine appropriate lipid lowering strategies for the cardiovascular patient.

### Criteria for Success

Certificate of completion will be awarded based on the participant's attendance. A certificate of completion will be available upon completion of an online evaluation/claim credit form available at:

[akhcme.com/OHACC](http://akhcme.com/OHACC)

**Please claim your credit by October 31, 2024.**

If you have questions about this CE activity, please contact AKH Inc at [JGoldman@akhcme.com](mailto:JGoldman@akhcme.com).



**CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.**



In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Ohio Chapter, American College of Cardiology (OH ACC). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 4.75 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to

ACCME for the purpose of granting ABIM MOC credit.

### Nurses

Credit being awarded: 4.75 ANCC contact hours

### Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 4.75 contact hours.

## Physician Associate



AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

## Commercial Support

There is no commercial support for this activity.

DISCLOSURES		
Name	Relationship	Commercial Interest
Anish Amin, MD (faculty)	Consultant	Abbott; Biosense Webster; Boston Scientific; Medtronic; Phillips; Vektor Medical
Mina Chung, MD, FACC (faculty)	N/A	Nothing to disclose
Christina Fink, MD, FACC, FAAP, FACP (moderator)	N/A	Nothing to disclose
Adam Gonyeau, PharmD (faculty)	N/A	Nothing to disclose
Yan Naung Htay, MD (faculty)	N/A	Nothing to disclose
Mark Iler, MD, FACC (faculty)	N/A	Nothing to disclose
Jeffrey Kuvin, MD, FACC (faculty)	N/A	Nothing to disclose
Judith Mackall, MD (moderator)	Consultant	Abbott
Ahmed Maraey, MD (faculty)	N/A	Nothing to disclose
Sanjay Rajagopalan, MD, FACC (faculty)	Consultant	Bayer; Novartis
Benjamin Romer, MD (faculty)	N/A	Nothing to disclose
Ellen Sabik, MD (moderator)	N/A	Nothing to disclose
Paul Sorajja, MD, FACC (faculty)	Advisor	4C Medical; Abbott Structural (Cephea, Global Valve Masters, Global Complexity Score, Tricuspid Advisory Board); Boston Scientific; SHV Strategic; vDyne
	Consultant	4C Medical; Abbott Structural; Adona; Boston Scientific; Cultiv8; Edwards Lifesciences; Foldax; GE Medical; GLG; LAZA; Medtronic; Phillips; WL Gore; vDyne; xDot
	Researcher	Abbott; Boston Scientific; Edwards Lifesciences; Medtronic
	Steering Committee	REPAIR MR; EXPAND; WL Gore Pipeline; SUMMIT; TRILUMINATE; TRILUMINATE Eligibility Committee for Anatomy; G4 Adverse Leaflet Events; Neovasc
Kenneth Varian, MD, PhD (faculty; moderator)	Speaker	Pfizer
Emily Vrontos, PharmD, CDCES (faculty)	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations	N/A	Nothing to disclose
Dorothy Duffy, RPh (planner/reviewer)	N/A	Nothing to disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to disclose
Risha Bellomo PA-C (PA planner/reviewer)	N/A	Nothing to disclose
AKH Inc Staff and Planners	N/A	Nothing to disclose
OH ACC Staff and Planners	N/A	Nothing to disclose
<b>All of the relevant financial relationships listed for these individuals have been mitigated.</b>		

## Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

**Disclosure of Unlabeled Use and Investigational Product**

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.

If you would like to opt out from future communications from AKH please send an email to [optout@akhcme.com](mailto:optout@akhcme.com) with your information with "Opt Out" in the subject line.